Search
for
Sort by
Research 31–60 of 1000+
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Silicate-based therapy for inflammatory dilated cardiomyopathy by inhibiting the vicious cycle of immune inflammation via FOXO signaling
- Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Bisindolylmaleimide Protein-Kinase-C Inhibitors Delay the Decline in DNA Synthesis in Mouse Hair Follicle Organ Cultures
- Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Midazolam Inhibits Hippocampal Long-Term Potentiation and Learning through Dual Central and Peripheral Benzodiazepine Receptor Activation and Neurosteroidogenesis
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis through the Receptor, Gpr44
- A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
- Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Human umbilical cord mesenchymal stem cell therapy for atopic dermatitis through inhibition of neutrophil chemotaxis
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- General Dermatology
- The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Treatment guidelines in adult women
- Cisd2 deficiency impairs neutrophil function by regulating calcium homeostasis via Calnexin and SERCA
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib